Wanbury: USFDA nod for 9 Metformin DMFs, new Saudi and Mexico business

Compliance View source PDF Explain this filing

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.9%Reaction day

₹186.20

prior close

₹187.51

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%+3.2% vs market

Pharmaceuticals peers, median of 173sector+0.0%+3.9% vs sector

On the reaction day the stock moved 3.2 pts more than Nifty Microcap 250 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.7

10m

+0.0

15m

+0.6

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.9+0.7+3.2+0.0+3.9

Next day

+0.4-1.0+1.4-1.2+1.6

+0.1-3.6+3.7-3.0+3.1

-0.5-4.5+4.0-3.9+3.4

-4.5-6.8+2.3-5.1+0.7

-9.2-6.4-2.8-3.9-5.3

-6.9pendingpending-0.9-6.1

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wanbury got 9 No DMF Deficiency letters from USFDA for Metformin HCl DMF, plus similar nods for Paroxetine and Diphenhydramine HCl. Company is adding Quetiapine, Sitagliptin and Empagliflozin to its API pipeline. New Metformin DC business in Saudi Arabia has about Rs 10 crore annual revenue potential. A Mexico customer won a 2-year tender worth about Rs 15 crore per year.

Likely market impact

Multiple USFDA nods and new Saudi and Mexico contracts worth about Rs 25 crore yearly boost growth outlook.